CA2751627A1 — Pharmaceutical compositions resistant to abuse
Assigned to Egalet Ltd · Expires 2010-08-12 · 16y expired
What this patent protects
A pharmaceutical composition and a shell for a pharmaceutical composition, the shell comprising an outer shell wall having an inner surface and extending from a first end to a second end, the outer shell wall having an opening at the first end and a maximum thickness of at least …
USPTO Abstract
A pharmaceutical composition and a shell for a pharmaceutical composition, the shell comprising an outer shell wall having an inner surface and extending from a first end to a second end, the outer shell wall having an opening at the first end and a maximum thickness of at least 1.0 mm, the shell having a length in the range from 4 mm to 20 mm. The pharmaceutical composition may comprise a matrix composition in a cavity of the shell. Further disclosed is a method for testing abuse-resis-tance of pharmaceutical compositions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.